Frank M Laduca

US Patent:

7358337, Apr 15, 2008

Filed:

Aug 16, 2002

Appl. No.:

10/222345

Inventors:

Ted C. K. Lee - Matawan NJ, US
Amanda B. McBride - Turnersville NJ, US
Frank M. LaDuca - East Brunswick NJ, US

Assignee:

International Technidyne Corporation - Edison NJ

International Classification:

A61K 35/14

US Classification:

530380

Abstract:

A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is γ-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37 C.

US Patent:

7906299, Mar 15, 2011

Filed:

Apr 15, 2008

Appl. No.:

12/103456

Inventors:

Ted C. K. Lee - Matawan NJ, US
Amanda B. McBride - Turnersville NJ, US
Frank M. LaDuca - East Brunswick NJ, US

Assignee:

International Technidyne Corporation - Edison NJ

International Classification:

C12Q 1/56

US Classification:

435 13

Abstract:

A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is γ-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37 C.

US Patent:

20120282634, Nov 8, 2012

Filed:

Apr 23, 2012

Appl. No.:

13/453465

Inventors:

Gary Hughes - Anderson IN, US
Aniruddha Patwardhan - Indianapolis IN, US
Darby Mcchesney - Lawrenceville NJ, US
Robert Harper - Marlton NJ, US
Heather Tomeo - Avon IN, US
Frank LaDuca - East Brunswick NJ, US

Assignee:

Polymer Technology Systems, Inc. - Indianapolis IN

International Classification:

G01N 33/566

US Classification:

435 725

Abstract:

A dry test strip layer for filtering red blood cells includes a Borosilicate Glass Fiber layer and lectin, impregnated in the borosilicate layer, such that the dry test strip is configured to filter red blood cells from a blood sample.

US Patent:

20130295678, Nov 7, 2013

Filed:

May 1, 2013

Appl. No.:

13/874971

Inventors:

Timothy Riley - Indianapolis IN, US
Aniruddha Patwardhan - Indianapolis IN, US
Frank LaDuca - East Brunswick NJ, US

Assignee:

Polymer Technology Systems, Inc. - Indianapolis IN

International Classification:

G01N 21/78

US Classification:

436 71, 422422

Abstract:

In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including POE-POP-POE block copolymer, a surfactant, and a reflectivity changing reactant, the POE-POP-POE block copolymers solubilizing essentially only non-LDL cholesterol analytes, the non-LDL cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample.

US Patent:

62485474, Jun 19, 2001

Filed:

Dec 17, 1993

Appl. No.:

8/169968

Inventors:

Frank M. LaDuca - East Brunswick NJ

Assignee:

International Technidyne Corp. - Edison NJ

International Classification:

C12R 156

US Classification:

435 13

Abstract:

A cocktail reagent preparation for the rapid production of serum contains thrombin, snake venom, and protamine sulfate. The preparation employs very small quantities of clot promoting substances which behave in a synergistic manner such that rapid clotting of highly heparinized blood is achieved without altering the chemical analysis of the blood enzymes, proteins, sugars, or electrolytes. Thus, clinicians who rely upon the results of such tests can more closely monitor organ and tissue function and adjust patient therapies accordingly.

US Patent:

53189108, Jun 7, 1994

Filed:

Jan 14, 1993

Appl. No.:

8/004495

Inventors:

Frank M. LaDuca - East Brunswick NJ

Assignee:

International Technidyne Corp. - Edison NJ

International Classification:

G01N 3100

US Classification:

436 8

Abstract:

A standard whole blood composition is disclosed, which is useful as a pooled human hemostasis reference standard in blood coagulation assays including Activated Clotting Time (ACT), Whole Blood Prothrombin Time (WBPT), Whole Blood Activated Partial Thromboplastin Time (WBAPTT) and Whole Blood Thrombin time (WBTT). Also disclosed are methods for determining the human standardized potency of heparin and protamine.

US Patent:

53023480, Apr 12, 1994

Filed:

Dec 10, 1992

Appl. No.:

7/988672

Inventors:

Robert Cusack - Edison NJ
Frank M. Laduca - East Brunswick NJ
Robert J. Samo - Lakewood NJ

Assignee:

ITC Corporation - Edison NJ

International Classification:

G01N 2103
G01N 3386

US Classification:

422 73

Abstract:

An apparatus and method for performing a coagulation time test on a sample of blood wherein the blood is deposited in a fluid reservoir and disposable cuvette. Within the cuvette is formed a capillary conduit have at least one restricted region. The cuvette is inserted into a testing machine which engages the cuvette and draws blood from the fluid reservoir into the capillary conduit. The blood is then caused to reciprocally move within the capillary conduit whereby the blood is forced to traverse the restricted region. The testing machine measures the time required each time the blood is caused to traverse the restricted region. When a measured time is a predetermined percentage longer than an immediately preceding time, coagulation is considered to have occurred and the overall coagulation time is displayed to the operator.

US Patent:

53729463, Dec 13, 1994

Filed:

Jan 6, 1994

Appl. No.:

8/178060

Inventors:

Robert Cusak - Edison NJ
Frank M. Laduca - East Brunswick NJ
Robert J. Samo - Lakewood NJ

Assignee:

International Technidyne Corporation - Edison NJ

International Classification:

G01N 2103
G01N 3386

US Classification:

436 69

Abstract:

The present invention is an apparatus and method for performing a coagulation time test on a sample of blood wherein the blood is deposited in a fluid reservoir and disposable cuvette. Within the cuvette is formed a capillary conduit have at least one restricted region. The cuvette is inserted into a testing machine which engages the cuvette and draws blood from the fluid reservoir into the capillary conduit. The blood is then caused to reciprocally move within the capillary conduit whereby the blood is forced to traverse the restricted region. The testing machine measures the time required each time the blood is caused to traverse the restrict region. When a measured time is a predetermined percentage longer than an immediately preceding time, coagulation is considered to have occured and the overall coagulation time is displayed to the operator.